Special Issue "Neuroblastoma Pathogenesis and Therapy"
Deadline for manuscript submissions: 31 July 2022.
Interests: pediatric cancers; neuroblastoma; cancer stem cells; metastasis; signaling pathways in cancer; immunotherapy; epigenetics; genetics; small molecule inhibitors; translational therapeutics; p53-myc interaction
Special Issues, Collections and Topics in MDPI journals
Neuroblastoma is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system. High-risk neuroblastoma accounts for almost 15% of all pediatric cancer-related deaths, with overall survival rates lower than 50%. This situation become murkier when the majority of neuroblastoma patients relapse with an aggressive, refractory, and metastatic disease, with an overall survival rate of only 10%. Therefore, understanding the causes of neuroblastoma pathogenesis, relapse, and developing novel therapeutic approaches is mandatory to effectively cure neuroblastoma.
Neuroblastoma is a highly heterogeneous tumor both from a clinical and a molecular perspective. The clinical impact and unique biology of neuroblastoma have made this aggressive solid tumor an interesting disease model for concerted translational research efforts. These efforts include novel insights into neuroblastoma tumor biology, molecular and epigenetic mechanisms, novel targeted therapeutic approaches including small molecule inhibitors, epigenetic, non-coding RNA, and cell-based immunologic therapies.
In this Special Issue, we invite authors to contribute articles focusing on different aspects of neuroblastoma tumor biology, pathogenesis, developmental therapeutics, and treatment approaches. The collected articles in this Special Issue will further enhance our knowledge and understanding of the complex neuroblastoma pathogenesis and drive the development of novel therapeutic strategies.
Dr. Saurabh Agarwal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Pediatric cancers
- Neural crest
- Therapeutic approach
- Signaling mechanisms
- Epithelial-to-mesenchymal transition